Specification
| Target | EGFR |
| Clone | Cetuximab |
| Isotype | Human IgG1(E356D/M358L)-Kappa |
| Expression System | CHO |
| Purification | Protein A |
| Recommended Isotope Control | Anti-HEL Human IgG1(E356D/M358L)-Kappa Isotype control |
| Recommended Dilution Buffer | PBS, pH 7.27 |
| Formulation | PBS, pH 7.4,Contains no stabilizers or preservatives |
| Endotoxin | <1EU/mg Determined by LAL gel clotting assay |
| Purity | >95% Determined by SDS-PAGE |
| Sterility | 0.2 μM filtered |
| Storage | This antibody can be storaged at 2°C to 8 °C for 2 weeks under sterile conditions;-20°C for 3 months under sterile conditions;-70°C for 36 months under sterile conditions.Avoid repeated freeze-thaw. |
| Disclaim | For Research Use Only |
Background
| Background | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).4 EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.9 EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells 4 and EGFR overexpression has been linked to more advanced disease and poor prognosis.EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.In vitro, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. |
QC Data
| Note | Please contact us for QC Data |
| Product Image (Reference Only) |  |